According to an announcement from Tianjin Development (00882), its indirectly held subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd. (Lisheng Pharmaceutical), reported total operating revenue of 1.007 billion yuan for the nine months ending September 30, 2025, a year-on-year decrease of 1.61%. The net profit attributable to shareholders of the parent company was 371 million yuan, marking a significant year-on-year increase of 119.05%. The basic earnings per share amounted to 1.44 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.